Synthesis and in vitro evaluation of MR molecular imaging probes using J591 mAb-conjugated SPIONs for specific detection of prostate cancer

Contrast Media and Molecular Imaging

Volumn 8, Issue 2, 2013, Pages 175-184

  Abdolahi, Mohammad ^a   Shahbazi Gahrouei, Daryoush ^a   Laurent, Sophie ^b   Sermeus, Corine ^b   Firozian, Farzin ^c   Allen, Barry J ^d   Boutry, Sebastien ^b,e   Muller, Robert N ^b,e  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b UNIVERSITY OF MONS   (Belgium)

^c ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

^e Center for Microscopy and Molecular Imaging   (Belgium)

Author keywords

Magnetic resonance imaging; Nanoprobe; Prostate cancer; Prostate specific membrane antigen (PSMA); Superparamagnetic iron oxide nanoparticles

Indexed keywords

MONOCLONAL ANTIBODY J591; PROSTATE SPECIFIC MEMBRANE ANTIGEN; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE;

ANTIGEN BINDING; ARTICLE; CANCER CELL CULTURE; CANCER DIAGNOSIS; CELL SURFACE; CELL TYPE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; IN VITRO STUDY; MOLECULAR IMAGING; MOLECULAR PROBE; NANOPROBE; NUCLEAR MAGNETIC RESONANCE IMAGING; PARTICLE SIZE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION;

ANTIBODIES, MONOCLONAL; CELL LINE, TUMOR; CONTRAST MEDIA; HUMANS; IMMUNOASSAY; MAGNETIC RESONANCE IMAGING; MAGNETITE NANOPARTICLES; MALE; MOLECULAR PROBE TECHNIQUES; MOLECULAR PROBES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 84871650896     PISSN: 15554309     EISSN: 15554317     Source Type: Journal    
DOI: 10.1002/cmmi.1514     Document Type: Article

References (43)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60(5):277-300; epub 2010/07/09.
2. Kelly KA, Setlur SR, Ross R, Anbazhagan R, Waterman P, Rubin MA, et al. Detection of early prostate cancer using a hepsin-targeted imaging agent. Cancer Res 2008;68(7):2286-2291; epub 2008/04/03.
3. Emonds KM, Swinnen JV, Mortelmans L, Mottaghy FM. Molecular imaging of prostate cancer. Methods 2009;48(2):193-199; epub 2009/04/14.
4. Lee CM, Jeong HJ, Cheong SJ, Kim EM, Kim DW, Lim ST, et al. Prostate cancer-targeted imaging using magnetofluorescent polymeric nanoparticles functionalized with bombesin. Pharm Res 2010;27(4):712-721; epub 2010/02/26.
5. Candas B, Cusan L, Gomez JL, Diamond P, Suburu RE, Levesque J, et al. Evaluation of prostatic specific antigen and digital rectal examination as screening tests for prostate cancer. Prostate 2000;45(1):19-35; epub 2000/08/29.
6. Bennett CL, Tosteson TD, Schmitt B, Weinberg PD, Ernstoff MS, Ross SD. Maximum androgen-blockade with medical or surgical castration in advanced prostate cancer: a meta-analysis of nine published randomized controlled trials and 4128 patients using flutamide. Prostate Cancer Prostatic Dis 1999;2(1):4-8; epub 2002/12/24.
7. Caubet JF, Tosteson TD, Dong EW, Naylon EM, Whiting GW, Ernstoff MS, et al. Maximum androgen blockade in advanced prostate cancer: a meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens. Urology 1997;49(1):71-78; epub 1997/01/01.
8. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. New Engl J Med 2004;351(15):1502-1512; epub 2004/10/08.
9. Li Y, Cozzi PJ, Russell PJ. Promising tumor-associated antigens for future prostate cancer therapy. Med Res Rev 2010;30(1):67-101; epub 2009/06/19.
10. Ravizzini G, Turkbey B, Kurdziel K, Choyke PL. New horizons in prostate cancer imaging. Eur J Radiol 2009;70(2):212-226; epub 2008/11/11.
11. Futterer JJ, Heijmink SW, Spermon JR. Imaging the male reproductive tract: current trends and future directions. Radiol Clin N Am 2008;46(1):133-147, vii; epub 2008/03/11.
12. Garin JA, Mas AG. Metodos diagnosticos de la diseminacion prostatica. [The diagnosis of prostate cancer dissemination.] Arch Esp Urol 2006;59(10):1011-1020; epub 2007/02/08.
13. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. Screening and prostate-cancer mortality in a randomized European study. New Engl J Med 2009;360(13):1320-1328; epub 2009/03/20.
14. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level
15. Steuber T, Helo P, Lilja H. Circulating biomarkers for prostate cancer. World J Urol 2007;25(2):111-119; epub 2007/03/09.
16. Kelloff GJ, Choyke P, Coffey DS. Challenges in clinical prostate cancer: role of imaging. AJR Am J Roentgenol 2009;192(6):1455-1470; epub 2009/05/22.
17. Karam JA, Mason RP, Koeneman KS, Antich PP, Benaim EA, Hsieh JT. Molecular imaging in prostate cancer. J Cell Biochem 2003;90(3):473-483; epub 2003/10/03.
18. DeGrado TR, Coleman RE, Wang S, Baldwin SW, Orr MD, Robertson CN, et al. Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer. Cancer Res 2001;61(1):110-117; epub 2001/02/24.
19. Kwee SA, Wei H, Sesterhenn I, Yun D, Coel MN. Localization of primary prostate cancer with dual-phase 18F-fluorocholine PET. J Nucl Med 2006;47(2):262-269; epub 2006/02/04.
20. Mazaheri Y, Shukla-Dave A, Muellner A, Hricak H. MRI of the prostate: clinical relevance and emerging applications. J Magn Reson Imaging 2011;33(2):258-274; epub 2011/01/29.
21. Weissleder R. Molecular imaging in cancer. Science 2006;312(5777):1168-1171; epub 2006/05/27.
22. Massoud TF, Gambhir SS. Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Gene Dev 2003;17(5):545-580; epub 2003/03/12.
23. Artemov D, Mori N, Ravi R, Bhujwalla ZM. Magnetic resonance molecular imaging of the HER-2/neu receptor. Cancer Res 2003;63(11):2723-2727; epub 2003/06/05.
24. Bander NH, Trabulsi EJ, Kostakoglu L, Yao D, Vallabhajosula S, Smith-Jones P, et al. Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen. J Urol 2003;170(5):1717-1721.
25. Sokoloff RL, Norton KC, Gasior CL, Marker KM, Grauer LS. A dual-monoclonal sandwich assay for prostate-specific membrane antigen: levels in tissues, seminal fluid and urine. Prostate 2000;43(2):150-157.
26. Wright GL, Jr, Haley C, Beckett ML, Schellhammer PF. Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues. Urol Oncol 1995;1(1):18-28; epub 1995/01/01.
27. Patri AK, Myc A, Beals J, Thomas TP, Bander NH, Baker JR, Jr. Synthesis and in vitro testing of J591 antibody-dendrimer conjugates for targeted prostate cancer therapy. Bioconjug Chem 2004;15(6):1174-1181; epub 2004/11/18.
28. Chang SS, Reuter VE, Heston WD, Bander NH, Grauer LS, Gaudin PB. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res 1999;59(13):3192-3198; epub 1999/07/09.
29. Meighan MA, Dickerson MT, Glinskii O, Glinsky VV, Wright GL Jr, Deutscher SL. Recombinant glutamate carboxypeptidase II (prostate specific membrane antigen - PSMA) - cellular localization and bioactivity analyses. J Protein Chem 2003;22(4):317-326; epub 2003/09/19.
30. Carter RE, Feldman AR, Coyle JT. Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase. Proc Natl Acad Sci USA 1996;93(2):749-753; epub 1996/01/23.
31. Smith-Jones PM, Vallabhajosula S, Navarro V, Bastidas D, Goldsmith SJ, Bander NH. Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor. J Nucl Med 2003;44(4):610-617; epub 2003/04/08.
32. Wolf P, Freudenberg N, Buhler P, Alt K, Schultze-Seemann W, Wetterauer U, et al. Three conformational antibodies specific for different PSMA epitopes are promising diagnostic and therapeutic tools for prostate cancer. Prostate 2010;70(5):562-569; epub 2009/11/26.
33. Liu H, Moy P, Kim S, Xia Y, Rajasekaran A, Navarro V, et al. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res 1997;57(17):3629-3634; epub 1997/09/01.
34. Li Y, Tian Z, Rizvi SM, Bander NH, Allen BJ. In vitro and preclinical targeted alpha therapy of human prostate cancer with Bi-213 labeled J591 antibody against the prostate specific membrane antigen. Prostate Cancer Prostat Dis 2002;5(1):36-46; epub 2004/06/15.
35. Holland JP, Divilov V, Bander NH, Smith-Jones PM, Larson SM, Lewis JS. 89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo. J Nucl Med 2010;51(8):1293-1300; epub 2010/07/28.
36. Pandit-Taskar N, O'Donoghue JA, Morris MJ, Wills EA, Schwartz LH, Gonen M, et al. Antibody mass escalation study in patients with castration-resistant prostate cancer using 111In-J591: lesion detectability and dosimetric projections for 90Y radioimmunotherapy. J Nucl Med 2008;49(7):1066-1074; epub 2008/06/17.
37. Roch A, Muller RN, Gillis P. Theory of proton relaxation induced by superparamagnetic particles. J Chem Phys 1999;110(11):5403-5411.
38. Forge D, Gossuin Y, Roch A, Laurent S, Elst LV, Muller RN. Development of magnetic chromatography to sort polydisperse nanoparticles in ferrofluids. Contrast Media Mol Imag 2010;5(3):126-132.
39. Serda RE, Adolphi NL, Bisoffi M, Sillerud LO. Targeting and cellular trafficking of magnetic nanoparticles for prostate cancer imaging. Mol Imaging 2007;6(4):277-288; epub 2007/08/23.
40. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65(1-2):55-63; epub 1983/12/16.
41. Bander NH, Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ. Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol 2005;23(21):4591-4601; epub 2005/04/20.
42. Rabin Y. Is intracellular hyperthermia superior to extracellular hyperthermia in the thermal sense? Int J Hyperthermia 2002;18(3):194-202; epub 2002/05/25.
43. Haase C, Nowak U. Role of dipole-dipole interactions for hyperthermia heating of magnetic nanoparticle ensembles. Phys Rev B 2012;85(4):045435.